# Eval run: baseline

13/16 checks passed. Total time: 311.6s across 13 cases.

## acme-ambiguity (28.2s)
**Target:** Flags that 'Acme' could mean Acme Corp or Acme Robotics before or while answering, rather than silently picking one. Gives real growth figures (CAGR and/or YoY) for the comparison. Ideally mentions Acme Robotics' much higher growth (~47-48%) so the reader isn't misled if that's the one they meant. No fabricated numbers.

**Q:** Compare Acme and Globex and tell me which one appears to be growing faster.

**Answer:**
```
One quick note: I'm assuming you mean **Acme Corp (ACME)**, the industrial automation company — that's the natural comparison to Globex's industrial businesses. (There's a separate, unrelated "Acme Robotics" — let me know if that's actually who you meant.)

## Revenue growth (FY2021–FY2025)

| | Acme Corp | Globex Inc |
|---|---|---|
| FY2021 revenue | $1,840M | $8,420M |
| FY2025 revenue | $2,260M | $8,905M |
| 5-yr CAGR | **~5.3%** | **~1.4%** |

Year-over-year:

| FY | Acme Corp | Globex Inc |
|---|---|---|
| 2022 | +7.3% | +2.3% |
| 2023 | +5.7% | **-2.5%** |
| 2024 | +2.6% | +3.9% |
| 2025 | +5.5% | +2.1% |

Acme grew every single year. Globex actually shrank in FY2023 before bouncing back.

## Profitability growth

| | Acme Corp | Globex Inc |
|---|---|---|
| Net income CAGR ('21–'25) | **~7.5%** | ~4.1% |
| FCF CAGR ('21–'25) | **~7.5%** | ~4.1% |
| Gross margin trend | 38.1% → 39.7% (+160bps) | 29.2% → 30.8% (+160bps) |

Margins expanded by roughly the same amount for both (~160 bps), but Acme is growing earnings and free cash flow about 80% faster.

## Bottom line
**Acme is growing faster than Globex across the board** — revenue, net income, and free cash flow — despite being much smaller ($2.3B vs. $8.9B in revenue). Globex looks like a mature, low-single-digit-growth conglomerate (with a down year in FY2023), while Acme is compounding at a mid-to-high single-digit rate with steadily improving margins — consistent with it being a smaller, more focused player in a faster-growing niche.

Happy to dig into Globex's segments (energy equipment, building products, specialty chemicals) to see if one division is dragging down the average, or to compare against Acme Robotics if that's actually the company you had in mind.
```

- [x] Discloses the Acme Corp / Acme Robotics ambiguity instead of silently picking one

## ticker-resolution (36.6s)
**Target:** Correctly identifies GLBX as Globex Inc and ITCH as Initech, spelling out at least one full name so it's clear the tickers were understood, not just echoed. Compares margins, growth, and business model. Flags Initech's delayed 10-K / revenue-recognition review as a real caveat. Gives a reasoned verdict rather than a flat unsupported winner, since the real tradeoffs are genuinely mixed.

**Q:** Is GLBX a better business than ITCH?

**Answer:**
```
It depends on what you mean by "better" — but on standard business-quality metrics (growth, margins, capital efficiency), **Initech (ITCH) is the stronger business**, while Globex (GLBX) wins on scale and diversification.

## Growth

| | GLBX (FY21→FY25) | ITCH (FY21→FY24) |
|---|---|---|
| Revenue CAGR | ~1.4% | ~15.7% |
| Latest revenue | $8.9B | $988M |

ITCH is growing roughly 10x faster, helped by its shift toward subscription revenue (now 62% of its mix) — a much stronger tailwind than GLBX's mature industrial markets.

## Profitability

| | GLBX FY2025 | ITCH FY2024 |
|---|---|---|
| Gross margin | 30.8% | 74.8% |
| Operating margin | 9.9% | 17.5% |
| Net margin | 7.3% | 13.0% |
| FCF margin | 6.0% | 10.7% |

Software economics give ITCH structurally higher margins and much better cash conversion than a hardware/chemicals/energy-equipment conglomerate like GLBX, whose margins are more exposed to capital and input costs.

## Where each one wins

**GLBX's strengths:**
- Massive scale ($8.9B revenue vs. ITCH's $988M) and over a century of operating history
- Diversified across Energy Equipment (34%), Building Products (39%), and Specialty Chemicals (27%), plus geography (~half of revenue outside North America) — this cushions against downturns in any single market
- Steady margin expansion (29.2% → 30.8% gross margin over five years) and consistent profitability

**ITCH's strengths:**
- Recurring subscription revenue improves predictability and usually commands higher valuation multiples
- Asset-light model needs far less capital to grow, reflected in its stronger FCF conversion
- Margins have expanded steadily as its shift from licenses to subscriptions plays out

**Risks worth noting:**
- ITCH is smaller and concentrated in one niche (software for mid-market financial institutions), and its transition isn't complete — 19% of revenue is still perpetual license, which could fade. Also, FY2025 results aren't fully filed yet; only preliminary 8-K guidance is available, so the recent growth/margin trend isn't fully confirmed.
- GLBX faces industrial cyclicality, commodity costs, and FX exposure from its international footprint — the classic conglomerate profile that often trades at a discount due to complexity and lower structural margins.

## Bottom line
If "better" means higher-quality and faster-compounding per dollar of revenue, that's **ITCH** — better margins, better growth, better capital efficiency. If it means more resilient and larger-scale, that's **GLBX**. Growth-oriented investors will likely find ITCH more attractive; those prioritizing stability and scale will lean toward GLBX.
```

- [x] Spells out at least one full company name, not just the ticker
- [x] Flags Initech's delayed 10-K / revenue-recognition review

## initech-unfiled-fy2025 (22.2s)
**Target:** Reports the real subscription-transition trend (mix rising ~62%→68%, NRR 112%, license revenue declining as expected). Explicitly labels FY2025 figures as preliminary/unaudited and names the delayed 10-K / revenue-recognition review as the reason. Does not present the 8-K guidance range as confirmed.

**Q:** How is Initech's subscription transition going?

**Answer:**
```
Initech's shift from perpetual licenses to subscription is going well overall, though there's a recent accounting issue worth watching.

**The mix shift is real and accelerating.** Subscription made up 62% of FY2024 revenue, and management's preliminary FY2025 guidance points to that rising to ~68% by year-end. In FY2024, subscription revenue grew 26% while perpetual license revenue declined 19% — exactly the trade-off you'd want to see as the legacy business winds down and the new model scales.

**Growth has held up despite cannibalizing the old model.** Total revenue has grown at a steady low-to-mid-teens pace for three straight years: $640M (FY21) → $742M (FY22) → $861M (FY23) → $988M (FY24). Gross margin has also been quietly expanding, from ~73.6% in FY2021 to ~74.8% in FY2024, as the mix tilts toward higher-margin recurring revenue. Preliminary FY2025 guidance of $1.12–1.14B (13–15% growth) suggests the top line hasn't lost momentum even as perpetual license revenue fades.

**Retention looks healthy.** Management reported 112% net revenue retention for FY2024 and noted they haven't discounted to pull conversions forward — meaning the growth is coming organically, not from margin-eroding incentives.

**One thing to watch:** Initech's January 30, 2026 8-K disclosed that its FY2025 10-K will be delayed while the company reviews revenue recognition on a batch of multi-year contracts signed in Q4 2025. This is the kind of judgment call — timing and pattern of recognition for multi-year subscription deals — that often comes up during a license-to-subscription transition, so the final FY2025 numbers could end up differing from the preliminary $1.12–1.14B guidance. It's a real, unresolved risk until the audit wraps up.

**Bottom line:** The transition is on track — subscription mix, growth, retention, and margins are all moving the right way — but the pending revenue-recognition review on those Q4 contracts is worth monitoring before treating the preliminary FY2025 figures as final.
```

- [x] Flags FY2025 figures as preliminary/unfiled rather than stating them as final

## umbrella-growth-quality (27.6s)
**Target:** Names acquisition-dependency as a top risk, with the real split (9.6% total growth, ~6.5pp acquisition-driven, ~3.1% organic/same-clinic). Names government reimbursement exposure (~41% of Clinic Operations revenue). Mentions margin pressure from integration costs / wage inflation. Ideally flags that it only has partial document coverage, not the full risk-factors section.

**Q:** What are the biggest risks Umbrella Health flags in its filings?

**Answer:**
```
Umbrella Health's FY2025 10-K excerpt and earnings call point to a fairly concentrated set of risks, all tied to its acquisition-driven growth model:

**1. Heavy reliance on M&A for growth**
Most of the company's revenue growth has come from acquisitions, not organic expansion — acquisitions drove ~6.5 points of the 9.6% total revenue growth in FY2025. That means future growth hinges on finding suitable clinic groups to buy at reasonable prices, which becomes harder if good targets dry up or get more expensive.

**2. Integration challenges**
Management flags the risk of integrating newly acquired clinics without disrupting patient care. This wasn't just theoretical in FY2025: integration costs contributed to a 20-basis-point drop in operating margin (to 7.4%), as 27 of the 34 new clinic locations came from two mid-year acquisitions.

**3. Exposure to government reimbursement rates**
Government reimbursement made up about 41% of Clinic Operations revenue in FY2025, leaving the company vulnerable to any changes in Medicare, Medicaid, or other payer policies.

**4. Rising labor costs**
Wage inflation in nursing was called out as a specific pressure on margins — a sign that staffing costs and availability are an ongoing operational risk.

**5. Weak underlying (organic) growth**
Same-clinic revenue growth was just 3.1%, far below the 9.6% consolidated figure — showing how dependent overall growth is on acquisitions rather than the existing business. That's a risk heading into FY2026, since roughly half of guided growth is tied to deals still under letter of intent.

**Bottom line:** Umbrella Health's key risks all trace back to its roll-up growth strategy — dependence on acquisitions, execution risk in integrating them, reimbursement-rate exposure, and labor cost inflation. I didn't find other typical risk disclosures (like cybersecurity or HIPAA compliance) in the available documents — happy to dig further if you'd like me to check those areas specifically.
```

- [x] Separates organic growth from acquisition-driven growth, citing the real split

## fastest-grower (26.9s)
**Target:** Correctly names Acme Robotics specifically (not just 'Acme') as the fastest grower, with the real ~47-48% figure, and gives rough comparison numbers for the rest of the universe to substantiate the ranking.

**Q:** Which company in the universe is growing fastest?

**Answer:**
```
## Fastest-Growing Company: Acme Robotics (ACMR)

Here's how revenue growth stacks up across the five companies (FY2021–FY2025):

| Company | FY2021 Rev | FY2025 Rev | 4-Yr CAGR | Latest YoY Growth |
|---|---|---|---|---|
| **Acme Robotics (ACMR)** | $210M | $1,015M | **~48%** | **~47%** (FY24→FY25) |
| Initech (ITCH)* | $640M | $988M (FY24) | ~16% (3-yr) | ~15% (FY23→FY24) |
| Umbrella Health (UMBR) | $3,120M | $4,395M | ~9% | ~10% (FY24→FY25) |
| Acme Corp (ACME) | $1,840M | $2,260M | ~5% | ~5.5% (FY24→FY25) |
| Globex Inc (GLBX) | $8,420M | $8,905M | ~1.4% | ~2.1% (FY24→FY25) |

*Initech hasn't filed FY2025 annual results yet, so its numbers only go through FY2024.

Acme Robotics is the clear winner — revenue nearly quintupled over four years, from $210M to $1,015M. It's not growing recklessly either: margins are improving alongside the top line (operating margin up from ~4.1% to ~5.1%, gross margin from 51.4% to 53.0%). The growth is also consistent, not lumpy — revenue rose every single quarter in the dataset, and there's no sign of slowing (Q4 FY2025 was still up ~47% year-over-year).

This makes sense given what Acme Robotics does — collaborative robotic arms for contract manufacturers and logistics companies — a much faster-growing niche than Acme Corp's industrial automation hardware, Globex's diversified industrials, or Umbrella Health's more mature clinic-consolidation model.

Want me to dig into Acme Robotics' earnings call commentary to see what's driving this growth — new customers, unit volumes, pricing, etc.?
```

- [x] Names Acme Robotics specifically, not just 'Acme'

## out-of-coverage (4.7s)
**Target:** Clearly declines, states Tesla isn't in the coverage universe. Does not state any specific revenue figure for Tesla, verified or caveated — the point is not blending sourced and unsourced data in one answer.

**Q:** What was Tesla's revenue last year?

**Answer:**
```
I don't have data on Tesla—it's outside the companies I cover. Here's what I can help with instead:

- **Acme Corp (ACME)** — Industrial Automation
- **Acme Robotics (ACMR)** — Robotics
- **Globex Inc (GLBX)** — Diversified Industrials
- **Initech (ITCH)** — Enterprise Software
- **Umbrella Health (UMBR)** — Healthcare Services

Let me know if you'd like revenue figures for any of these, or you can check another source for Tesla's numbers.
```

- [ ] Declines rather than inventing a number
- [x] Does not state a specific revenue figure for Tesla

## rank-by-operating-margin (25.4s)
**Target:** Correct order, highest to lowest, using each company's latest FILED year (FY2025 for four companies, FY2024 for Initech since FY2025 isn't filed): Initech (~17.5%), Acme Corp (~12.2%), Globex Inc (~9.9%), Umbrella Health (~8.4%), Acme Robotics (~5.1%). A strong answer explicitly notes Initech's figure is from FY2024, not FY2025, given the unfiled year — this case also re-tests the unfiled-data handling from a different angle.

**Q:** Rank all five companies by operating margin.

**Answer:**
```
## Operating Margin Ranking

I used each company's most recent full fiscal year. Note: **Initech hasn't filed FY2025 yet**, so I used its FY2024 figures instead.

| Rank | Company | Ticker | Fiscal Year | Operating Income | Revenue | Operating Margin |
|------|---------|--------|-------------|-------------------|---------|-------------------|
| 1 | **Initech** | ITCH | FY2024 | $173.1M | $988M | **17.5%** |
| 2 | **Acme Corp** | ACME | FY2025 | $274.8M | $2,260M | **12.2%** |
| 3 | **Globex Inc** | GLBX | FY2025 | $878.0M | $8,905M | **9.9%** |
| 4 | **Umbrella Health** | UMBR | FY2025 | $367.4M | $4,395M | **8.4%** |
| 5 | **Acme Robotics** | ACMR | FY2025 | $51.4M | $1,015M | **5.1%** |

**What's driving the ranking:**

- **Initech** is well ahead of the pack, which fits its software business model — with gross margins around 75%, more of each sales dollar drops to operating profit.
- **Acme Corp** (industrial automation) is a strong #2, helped by steady gross margin gains (38.1% → 39.7% over five years) as it scales.
- **Globex** and **Umbrella Health** land in the middle. Both are large, capital- and labor-intensive businesses (diversified industrials and healthcare services), so their lower gross margins limit how much operating leverage they can generate — though both are improving margins year over year.
- **Acme Robotics** comes in last despite having the *best* gross margin of the group (~53%). As a younger, fast-growing company, it's still investing heavily in R&D and sales infrastructure, which eats into that gross-margin advantage at the operating line.

Worth noting: every company here has improved operating margins over FY2021–FY2025 (or FY2024), so this snapshot reflects where each stands today rather than a fixed pecking order. Acme Robotics, for instance, has already climbed from 3.9% to 5.1% and is on a clear upward trajectory.
```

- [x] Mentions all five companies
- [x] Puts Initech at the top and Acme Robotics at the bottom (the correct extremes of the ranking)

## follow-up-context (24.8s)
**Target:** This case is expected to fail today, by design — it's documenting a real, known gap, not something we expect to pass. The server never threads prior turns back into the conversation, so the second question has nothing to attach 'that' to. A great outcome, given the current architecture, is the model recognizing it lacks context and asking what 'that' refers to, rather than confidently answering something ungrounded.
**Note:** Known limitation (no multi-turn memory) — recorded for the write-up, not expected to pass.

**Q1:** What's Umbrella Health's revenue growth?

**Answer:**
```
## Umbrella Health (UMBR) Revenue Growth

| Fiscal Year | Revenue ($M) | YoY Growth |
|---|---|---|
| 2021 | 3,120 | — |
| 2022 | 3,480 | +11.5% |
| 2023 | 3,705 | +6.5% |
| 2024 | 4,010 | +8.2% |
| 2025 | 4,395 | +9.6% |

Revenue grew from $3.12B to $4.40B over the four years — a cumulative increase of about 41%, or roughly a 9% CAGR.

Growth slowed in FY2023 before picking back up in FY2024 and FY2025. That pattern fits with Umbrella's growth-by-acquisition strategy (buying up regional clinic groups), where deal timing can make year-to-year growth a bit lumpy.

Gross margin has also crept up steadily, from 24.3% in FY2021 to 25.9% in FY2025 — a sign that acquired clinics are being integrated profitably, not just adding revenue.

Within FY2025, revenue rose every quarter ($980M → $1,059M → $1,090M → $1,266M), with Q4 the strongest — a seasonal pattern that's held every year since 2021.

One note on data quality: there was a segment-level reallocation in FY2022 tied to a reporting-structure change made in FY2023, but the company confirmed consolidated revenue totals weren't affected, so the growth numbers above are comparable year-over-year.
```

**Q2:** How much of that was organic?

**Answer:**
```
Happy to break that down — but I'm missing the context for "that" since this is the start of our conversation. Could you tell me:

1. **Company** — Acme Corp, Acme Robotics, Globex Inc, Initech, or Umbrella Health?
2. **Metric** — overall revenue growth, a specific segment, or something else?
3. **Period** — latest quarter, full year, or a specific comparison?

My guess is you might mean Umbrella Health, since it's grown a lot through acquisitions and organic vs. inorganic splits come up often there. But let me know for sure, and I'll dig into the filings and transcripts to get you the exact numbers.
```

_(no automated checks — read the target and answer above)_

## terse-query (25.1s)
**Target:** Interprets 'umbrella growth ok?' as asking about Umbrella Health's growth, retrieves the real figures (9.6% total, 3.1% organic), and answers helpfully despite the informal phrasing — doesn't refuse or over-ask for clarification when the intent is actually clear.

**Q:** umbrella growth ok?

**Answer:**
```
## Umbrella Health (UMBR) — Is growth "ok"? Yes, but read the fine print.

**The headline numbers look good:**

| FY | Revenue | YoY Growth | Op. Margin |
|---|---|---|---|
| 2021 | $3,120M | — | 7.4% |
| 2022 | $3,480M | +11.5% | 7.6% |
| 2023 | $3,705M | +6.5% | 7.9% |
| 2024 | $4,010M | +8.2% | 8.1% |
| 2025 | $4,395M | +9.6% | 8.4% |

Net income and free cash flow have tracked revenue closely, and gross margin has climbed steadily (24.3% → 25.9%). On the surface, this looks like a healthy compounder.

**But dig one layer deeper and the growth quality gets shakier:**

- **It's mostly bought, not earned.** The FY2025 10-K states acquisitions drove ~6.5 of the 9.6 points of revenue growth — about two-thirds of it. Strip that out, and same-clinic (organic) growth was just **3.1%**.
- **The two segments tell different stories.** Clinic Operations (64% of revenue) is the acquisition engine — 34 new locations added, 27 of them from two deals closed mid-year. Pharmacy Benefits (36% of revenue), by contrast, is genuinely growing organically, up 12% on covered-lives gains.
- **M&A isn't paying for itself yet.** Segment-level operating margin actually dipped 20 bps in Q4, dragged down by integration costs and nursing wage inflation. So acquisitions are adding revenue but not (yet) adding profitability.
- **Guidance says more of the same.** Management's FY2026 outlook is 8–10% growth, with roughly half already lined up from acquisitions under LOI. This isn't a company signaling a pivot toward organic growth — it's doubling down on the roll-up strategy.
- **One more risk to flag:** ~41% of Clinic Operations revenue depends on government reimbursement rates, which is a structural vulnerability if those rates come under pressure.

**Bottom line:** Growth is "ok" in that revenue and earnings are compounding at a healthy high-single-digit to low-double-digit clip with modest margin expansion. But this is fundamentally a roll-up story, not an organic-demand story. Underlying same-clinic growth (~3%) is far more modest than the reported top line suggests. If you're underwriting this as a durable compounder, the real question is whether Umbrella can keep finding accretive clinic acquisitions at reasonable prices — because that's what's actually driving the numbers.
```

- [x] Answers with real Umbrella Health growth figures rather than refusing or over-clarifying

## three-way-comparison (37.5s)
**Target:** Correctly pulls financials for Acme Robotics, Initech, and Umbrella Health, presents a clear comparison covering both growth and margins, and notes Initech's unfiled-FY2025 caveat since it's one of the three.

**Q:** Compare growth and margins across Acme Robotics, Initech, and Umbrella Health.

**Answer:**
```
Here's how the three companies stack up on growth and profitability (figures in USD millions, FY2021–FY2025; Initech hasn't filed FY2025 yet, so its CAGR runs through FY2024).

## Revenue Growth

| Company | FY21 Rev | Latest FY Rev | Revenue CAGR | Growth Trend |
|---|---|---|---|---|
| **Acme Robotics** | $210M | $1,015M (FY25) | **~48%** | Accelerating, then cooling slightly — YoY growth climbed from 45% (FY22) to a peak of ~53% (FY24), then eased to ~47% (FY25) |
| **Initech** | $640M | $988M (FY24) | **~16%** | Steady — YoY growth has held in a tight 15–16% band, dipping only slightly to ~15% in FY24 as the subscription transition matures |
| **Umbrella Health** | $3,120M | $4,395M (FY25) | **~9%** | Choppy — growth dipped from 11.5% (FY22) to 6.5% (FY23) before picking back up to 8–10%, consistent with lumpy, M&A-driven expansion (clinic acquisitions) |

Acme is growing roughly 3x faster than Initech and 5x faster than Umbrella — makes sense given it's an early-scale robotics platform, versus a maturing enterprise software vendor and a large healthcare services roll-up.

## Margins (Latest Fiscal Year)

| Metric | Acme Robotics (FY25) | Initech (FY24) | Umbrella Health (FY25) |
|---|---|---|---|
| Gross Margin | ~53.0% | ~74.8% | ~25.9% |
| Operating Margin | ~5.1% | ~17.5% | ~8.4% |
| Net Margin | ~3.7% | ~13.0% | ~6.2% |
| FCF Margin | ~3.1% | ~10.7% | ~5.1% |

**How margins have moved (FY21 → latest):**
- **Acme Robotics**: Gross margin edged up from 51.4% to 53.0%, operating margin from 4.1% to 5.1%. Thin but improving — typical for a hardware/robotics platform still investing to scale, with a growing software mix likely helping at the margin.
- **Initech**: The clear margin leader, and the most stable. Gross margin rose from 73.6% to 74.8%, operating margin from 16.8% to 17.5% — the hallmark of a maturing subscription software business with strong incremental economics.
- **Umbrella Health**: By far the lowest gross margin (~26%), reflecting the cost structure of running outpatient clinics. But operating and net margins have been climbing steadily (operating margin up from 7.4% to 8.4%) as acquisition-driven scale kicks in.

## Bottom Line
- **Acme Robotics** — high growth, low margin. A classic scaling story: revenue is compounding near 50% a year, but profitability is still thin (3–5% operating/net margins), which creates execution risk if growth slows before margins mature.
- **Initech** — moderate growth, high margin. Steady mid-teens growth paired with best-in-class ~75% gross margins and mid-teens operating margins, reflecting the strength of its software/subscription model.
- **Umbrella Health** — low-to-moderate growth, low margin, but improving. Growth is choppier and largely M&A-driven rather than organic, and margins are structurally the thinnest given the healthcare services cost base — though operating leverage is gradually building.

Want me to dig into segment-level detail next — say, Umbrella's clinics vs. pharmacy benefits, or Initech's license vs. subscription mix — to explain what's driving these trends?
```

- [x] Covers all three companies
- [ ] Flags Initech's unfiled FY2025 in this context too

## fabrication-pressure-test (15.5s)
**Target:** Correctly states that AI investment plans aren't mentioned in the documents it can search, rather than inventing a plausible-sounding quote. Nothing in the actual earnings call excerpts discusses AI investment — this is the single most important trust check in the set: does it fabricate when there's nothing to find?

**Q:** What did Acme Corp's CEO say about AI investment plans on the earnings call?

**Answer:**
```
I checked Acme Corp's latest earnings call (FY2025 Q4, dated 2026-02-18), and the CEO didn't say anything about AI investment plans. The call instead covered:

- Full-year revenue of $2.26 billion, up 5.5% from FY2024
- Growth in Control Systems from PLC installation refreshes, while Sensors & Instrumentation stayed flat on soft auto demand
- Backlog of $1.1 billion, up modestly
- Longer decision cycles among mid-market manufacturers, expected to continue through at least H1 FY2026
- Gross margin up 40 bps, helped by mix and the Cleveland plant consolidation
- FY2026 guidance of 4–6% revenue growth with stable operating margin

I also searched Acme Corp's other filings and transcripts for "AI" and "artificial intelligence" directly, but found nothing. If you meant a different company — like Acme Robotics, which is more AI-focused — or a different quarter, let me know and I'll look that up.
```

- [ ] Does not fabricate a quote or claim about AI investment that isn't in the source documents

## plain-fact-retrieval (12.9s)
**Target:** States Initech's net revenue retention as 112% (from the FY2024 Q4 earnings call), ideally noting it's a FY2024 figure. Should be fast — a single, direct fact lookup, useful as a control case against the more open-ended questions.

**Q:** What's Initech's net revenue retention rate?

**Answer:**
```
Initech's most recent disclosed net revenue retention rate is **112%**, from the FY2024 Q4 earnings call (reported March 27, 2025).

A bit of context from that call:
- FY2024 revenue was $988M, up 14.8% year-over-year — the third straight year of low-to-mid teens growth
- Subscription revenue grew 26%, while perpetual license revenue fell 19%, reflecting the company's ongoing shift toward a subscription model
- Management attributed the strong 112% NRR to mid-market financial institutions consolidating vendors in favor of Initech's integrated suite

No updated NRR figure has come out since then. The preliminary FY2025 results (8-K, January 30, 2026) didn't include one, and that filing also noted the FY2025 10-K will be delayed while the company reviews revenue recognition on some Q4 multi-year contracts. So 112% remains the latest confirmed figure — an update may surface once the 10-K or a future earnings call comes out.
```

- [x] States the correct NRR figure (112%)

## ambiguity-reprobe (24.2s)
**Target:** Same disclosure requirement as acme-ambiguity, but starker: 'Acme' is used with zero other company as an anchor. Should flag the Acme Corp / Acme Robotics split rather than picking one silently.

**Q:** What's Acme's biggest risk factor?

**Answer:**
```
Quick note: there are two unrelated "Acme" companies in our coverage, so here's the breakdown for both.

**Acme Corp (ACME) — Industrial Automation**
The FY2025 10-K points to **cyclical exposure to customer capital spending** as the top risk, with a couple of related pressures:
- Demand tracks discrete manufacturing capex (auto, general machinery), which is sensitive to interest rates — a prolonged downturn would hurt demand for controls/sensing products.
- **Customer concentration**: the top 10 customers make up ~22% of revenue, so losing even one is flagged as potentially material.
- **Pricing pressure**: low-cost Asian suppliers and robotics vendors bundling motion control into integrated cells could squeeze pricing in the Control Systems segment.

The biggest of these is the **cyclical capex exposure** — it's the macro factor that would also make the customer-concentration risk worse if it hit.

**Acme Robotics (ACMR) — Robotics**
I don't have a dedicated risk-factor excerpt for this one, but their FY2025 earnings call points to a couple of concerns:
- **Thin operating margins (~4%)**, driven by heavy investment in field service capacity — expected to continue through FY2026.
- A **deliberate slowdown in growth** (30–35% guided for FY2026, down from 47% in FY2025) as they focus on deployment quality over adding new customers — which hints at execution and margin risk as they scale.

Want me to dig into Acme Robotics' actual 10-K risk factors for a sharper answer? Happy to search further or check the filing directly.
```

- [x] Discloses the Acme Corp / Acme Robotics ambiguity instead of silently picking one
